BioPharm International: Reducing Timelines and Eliminating the White Space in Complex Biologic & Bioconjugate Development

Our CSO, Dr Campbell Bunce, explains how our integrated drug development model combines front-end R&D, process development, and manufacturing under one roof.

Key Objectives

Click Here to Watch the Video Interview

Integrated contract development and manufacturing organizations (CDMOs) are increasingly being recognized for their ability to reduce the time and cost risks associated with fragmented, multi-provider drug development models. By housing R&D capabilities alongside process development and manufacturing, integrated platforms allow for overlapping workstreams and real-time data-driven decision-making. Campbell Bunce, CSO, Abzena, explains the company’s front-end R&D expertise spanning protein engineering, bioconjugation, and a broad range of analytical and bioassay capabilities, enabling Abzena to develop a deep understanding of each molecule before moving into the more expensive stages of development and manufacturing. Central to Abzena’s early-stage work is a focus on developability so liabilities can be designed out before they become costly downstream problems. Next-generation cell line development platforms are also playing a key role in accelerating timelines. Together, these capabilities are enabling developers to move stable pool materials off the critical path for activities such as analytical method development, downstream processing, and even toxicology studies, with the ultimate goal of getting more effective therapies to patients faster.